“State-of-the-Art Technology Platform to Partner with Cutting-edge Advisory Service for Precision Oncology”
SecondOpinionExpert, Inc. and Massive Bio, Inc. announced today that they are partnering to deliver expert medical second opinions and cutting-edge precision oncology advisory services to cancer patients, physicians and enterprises around the globe.
The partnership will combine SecondOpinionExpert’s innovative technology platform, which enables patients to receive expert medical second opinions that are quick, easy and affordable, along with Massive Bio’s cutting-edge precision oncology services to cancer patients, treating oncologists and enterprises. Massive Bio leverages healthcare informatics with a team of oncology experts and molecular diagnostic scientists from top academic cancer centers to provide prioritized testing and treatment recommendations to patients at their local point of care. By leveraging SecondOpinionExpert’s cutting edge information technology and network of top medical experts and Massive Bio’s world-class multidisciplinary cancer team of medical oncologists, molecular diagnostic scientists, reimbursement experts and data scientists, the partnership will make precision oncology accessible, affordable and personalized for patients around the globe.
“By combining Massive Bio’s next dimension of cancer care, where precision oncology knowledge unlocks meaningful time in the battle against cancer with SecondOpinionExpert’s unique technology platform, we will be able to save lives especially for patients who have exhausted standard of care options,” said Dr. Mohan Ananda, SecondOpinionExpert Chief Executive Officer.
The strategic partnership will allow patients already benefitting from the Massive Bio platform to seamlessly access the SecondOpinionExpert platform and viceversa.
“We are excited about leveraging the power of the SecondOpinionExpert technology platform and international footprint to reach more cancer patients. We translate state-of-the-art precision oncology expertise to patients and the overall cancer community, which significantly improves patient outcomes across the US and beyond while minimizing the high cost of cancer care, improving access to clinical trials and gaining precious time for patients” said Dr. Selin Kurnaz, Massive Bio’s Co-founder and CEO.
Posted in: Articles